PRME Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -9.2%, SMA50 -15.29%, SMA200 4.54%). The stock’s 14-day RSI is 39.98 (weak momentum), while the ATR of 0.29 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -50.43% below its high and over 209.91% above its low. Average 10-day trading volume of 2.60 million shares is below the 3-month average of 3.96 million, indicating normal recent market interest.

Prime Medicine, Inc. generated EPS of -$1.48 over the past year. Five-year average earnings growth is -124.13%. Wall Street analysts project EPS growth of 20.13% annually over the next five years. The latest quarter delivered EPS of -$0.32. The next quarter is forecast at -$0.25. Next year's EPS is expected at $5.24. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 7 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $4.25. The high target offers 365.12% upside. The low target suggests 23.55% downside. The mean target is $10.22. This offers 197.09% upside. Prime Medicine, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 07, 2025, missed forecasts by 21.21%. The prior quarter beat by 13.89%. Over the last six quarters, Apple has recorded several small beats. These include 15.0% in August 08, 2024.

Prime Medicine, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.19. This means the shares are trading above this model’s fair value.

Prime Medicine, Inc. (NASDAQ:PRME) closed at $3.44 USD, gaining $0.07 (2.08%) from the previous close of $3.37. The stock is currently mid-range between its 52-week high and low $1.11 and $6.94. With a market capitalization of about $608.89 million, Prime Medicine, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.71). Key stats such as the average daily volume over the past year has been around 4.03 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Prime Medicine, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Allan Reine, the company employs approximately 214 people and listed since October 20, 2022. Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology.

Prime Medicine, Inc. has 178.27 million shares outstanding. The public float is 58.40 million shares, elevated short interest at 16.94% of float. This equals 18.37 million shares. The short ratio is 3.98 days. Institutional investors hold 54.13% of the float. Insiders own 18.19%. Liu David R. holds 20.24 million shares, ARCH Venture Partners X, LLC has 6.23 million shares and ARCH Venture Partners XII, LLC has 6.23 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Prime Medicine, Inc. trades at a P/E ratio of -2.85, slightly below the S&P 500 average, with a price-to-sales ratio of 103.65 and a price-to-book ratio of 3.47 trading at moderately above to book value. The P/FCF stands at -5.79, also above market averages.

Prime Medicine, Inc. (NASDAQ:PRME) shares are up 17.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Prime Medicine, Inc. trading at a premium to the broader market with a P/E of -2.85. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $14.39, suggesting 318.31% upside. Our AI forecast model points to short-term weakness (-2.62% over two weeks), a medium-term fall (-67.73% over three months), and a longer-term gain (361.34% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Prime Medicine, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.62%, with price expected at $3.35 by January 13, 2026, within a range of $3.05 to $3.63 3-Month Outlook: Projected fall of -67.73%, reaching $1.11 by March 27, 2026, with a range of $0.90 to $1.24. 1-Year Outlook: Projected gain of 361.34%, with price at $15.87 by December 30, 2026, within a range of $14.22 to $18.41.